A compound of formula (I L) wherein R 1 is selected from the group consisting of C 1-4 alkyl, -C -NH 2, C 3-6 cycloalkyl, phenyl and 5 to 6 membered heteroaryl; wherein the heteroaryl is optionally substituted with one or more substituents independently selected from halogen and C 1-4 alkyl; n is an integer from 0 to 1; L is selected from the group consisting of -CH 2 CH 2 -N(CH 3)-, -CH 2 CH 2 -N(CH 2 CH 3)- and -CH 2 CH 2 CH 2 -NR A -; wherein R A is selected from the group consisting of hydrogen, methyl and ethyl; Y is selected from the group consisting of N and CH; X is selected from the group consisting of N(R B), O and S; wherein R B is selected from the group consisting of hydrogen and C 1-4 alkyl; R 2 is selected from the group consisting of hydrogen, halogen, nitro, -CO 2 H, -C -NR C R D, -Q, -O-Q and -C -NH-Q; wherein R C and R D are each independently selected from the group consisting of hydrogen and C 1-4 alkyl; alternatively, R C and R D are taken together with the nitrogen atom to which they are bound to form a ring structure selected from the group consisting of piperidin-1-yl, piperazin-1-yl, pyrrolidin-1-yl, morpholin-4-yl, 1,2,3,4-tetrahydroquinolin-1-yl and 1,2,3,4-tetrahydro-isoquinolin-2-yl; wherein Q is selected from the group consisting of aryl, aralkyl, heterocyclyl, benzo[d][1,3]dioxolyl and 2,3-dihydro-benzo[b][1,4]dioxinyl; wherein the aryl or heterocyclyl, whether alone or as part of a substituent group, is optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, C 1-4 alkyl, halogenated C 1-4 alkyl, C 1-4 alkoxy, halogenated C 1-4 alkoxy, -CO 2 H, -C -NR E R F, -SO 2 -NR E R F and phenyl; wherein R E and R F are each independently selected from the group consisting of hydrogen and C 1-4 alkyl; and wherein the heterocyclyl contains one or more S heteroatoms, said heterocyclyl may be further optionally substituted on said one or more S heteroatoms with one to two oxo groups; or a pharmaceutically acceptable salt thereof. R 1 is selected from the group consisting of C 1-4 alkyl, -C -NH 2, C 3-6 cycloalkyl, phenyl and 5 to 6 membered heteroaryl; wherein the heteroaryl is optionally substituted with one or more substituents independently selected from halogen and C 1-4 alkyl; n is an integer from 0 to 1; L is selected from the group consisting of -CH 2 CH 2 -N(CH 3)-, -CH 2 CH 2 -N(CH 2 CH 3)- and -CH 2 CH 2 CH 2 -NR A -; wherein R A is selected from the group consisting of hydrogen, methyl and ethyl; Y is selected from the group consisting of N and CH; X is selected from the group consisting of N(R B), O and S; wherein R B is selected from the group consisting of hydrogen and C 1-4 alkyl; R 2 is selected from the group consisting of hydrogen, halogen, nitro, -CO 2 H, -C -NR C R D, -Q, -O-Q and -C -NH-Q; wherein R C and R D are each independently selected from the group consisting of hydrogen and C 1-4 alkyl; alternatively, R C and R D are taken together with the nitrogen atom to which they are bound to form a ring structure selected from the group consisting of piperidin-1-yl, piperazin-1-yl, pyrrolidin-1-yl, morpholin-4-yl, 1,2,3,4-tetrahydroquinolin-1-yl and 1,2,3,4-tetrahydro-isoquinolin-2-yl; wherein Q is selected from the group consisting of aryl, aralkyl, heterocyclyl, benzo[d][1,3]dioxolyl and 2,3-dihydro-benzo[b][1,4]dioxinyl; wherein the aryl or heterocyclyl, whether alone or as part of a substituent group, is optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, C 1-4 alkyl, halogenated C 1-4 alkyl, C 1-4 alkoxy, halogenated C 1-4 alkoxy, -CO 2 H, -C -NR E R F, -SO 2 -NR E R F and phenyl; wherein R E and R F are each independently selected from the group consisting of hydrogen and C 1-4 alkyl; and wherein the heterocyclyl contains one or more S heteroatoms, said heterocyclyl may be further optionally substituted on said one or more S heteroatoms with one to two oxo groups;